Skip to main content

Emtricitabine / tenofovir Alafenamide News

Federal Judge Rules FDA, CDC Must Restore Health Websites Removed Under Trump Order

TUESDAY, Feb. 12, 2025 – A federal judge has ordered the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) to restore access to public health websites that...

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...

FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy

FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Pre-Exposure Prophylaxis, HIV Infection

Emtricitabine / tenofovir Alafenamide patient information at Drugs.com